$1.49
1.02% today
Nasdaq, Apr 03, 06:43 pm CET
ISIN
CA88338H1001
Symbol
THTX
Sector
Industry

Theratechnologies Inc. Target price 2025 - Analyst rating & recommendation

Theratechnologies Inc. Classifications & Recommendation:

Buy
50%
Hold
50%

Theratechnologies Inc. Price Target

Target Price $3.80
Price $1.47
Potential
Number of Estimates 1
1 Analyst has issued a Theratechnologies Inc. price target 2026. The average Theratechnologies Inc. target price is $3.80. This is higher than the current stock price.
A rating was issued by 2 analysts: 1 Analysts recommend Theratechnologies Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Theratechnologies Inc. stock has an average upside potential 2026 of . Most analysts recommend the Theratechnologies Inc. stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Nov '24 2025
Estimates
Revenue Million $ 85.87 85.28
5.03% 0.68%
EBITDA Margin 12.86% 21.14%
278.47% 64.43%
Net Margin -9.10% 7.01%
82.21% 177.01%

2 Analysts have issued a sales forecast Theratechnologies Inc. 2025 . The average Theratechnologies Inc. sales estimate is

$85.3m
Unlock
. This is
0.68% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$87.5m 1.86%
Unlock
, the lowest is
$83.1m 3.23%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $85.9m 5.03%
2025
$85.3m 0.68%
Unlock
2026
$92.5m 8.52%
Unlock
2027
$102m 9.91%
Unlock
2028
$115m 12.69%
Unlock
2029
$124m 7.92%
Unlock

1 Analyst has issued an EBITDA forecast Theratechnologies Inc. 2025 . The average Theratechnologies Inc. EBITDA estimate is

$18.0m
Unlock
. This is
71.06% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$18.0m 71.06%
Unlock
, the lowest is
$18.0m 71.06%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $11.0m 287.44%
2025
$18.0m 63.32%
Unlock
2026
$31.2m 73.29%
Unlock
2027
$42.5m 36.06%
Unlock
2028
$57.7m 35.76%
Unlock
2029
$65.2m 13.06%
Unlock

EBITDA Margin

2024 12.86% 278.47%
2025
21.14% 64.43%
Unlock
2026
33.76% 59.70%
Unlock
2027
41.79% 23.79%
Unlock
2028
50.35% 20.48%
Unlock
2029
52.74% 4.75%
Unlock

2 Theratechnologies Inc. Analysts have issued a net profit forecast 2025. The average Theratechnologies Inc. net profit estimate is

$6.0m
Unlock
. This is
168.45% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$7.4m 184.25%
Unlock
, the lowest is
$4.6m 152.65%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-7.8m 81.32%
2025
$6.0m 176.50%
Unlock
2026
$9.7m 61.54%
Unlock
2027
$13.1m 35.61%
Unlock
2028
$21.4m 63.21%
Unlock
2029
$25.5m 19.36%
Unlock

Net Margin

2024 -9.10% 82.21%
2025
7.01% 177.01%
Unlock
2026
10.43% 48.79%
Unlock
2027
12.88% 23.49%
Unlock
2028
18.65% 44.80%
Unlock
2029
20.63% 10.62%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Nov '24 2025
Estimates
Earnings Per Share $ -0.17 0.13
81.32% 176.47%
P/E 11.31
EV/Sales 0.72

2 Analysts have issued a Theratechnologies Inc. forecast for earnings per share. The average Theratechnologies Inc. EPS is

$0.13
Unlock
. This is
168.42% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.16 184.21%
Unlock
, the lowest is
$0.10 152.63%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.17 81.32%
2025
$0.13 176.47%
Unlock
2026
$0.21 61.54%
Unlock
2027
$0.29 38.10%
Unlock
2028
$0.47 62.07%
Unlock
2029
$0.56 19.15%
Unlock

P/E ratio

Current -7.87 352.30%
2025
11.31 243.71%
Unlock
2026
7.00 38.11%
Unlock
2027
5.16 26.29%
Unlock
2028
3.16 38.76%
Unlock
2029
2.65 16.14%
Unlock

Based on analysts' sales estimates for 2025, the Theratechnologies Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.72 0.00%
2025
0.72 0.28%
Unlock
2026
0.67 7.85%
Unlock
2027
0.61 9.02%
Unlock
2028
0.54 11.27%
Unlock
2029
0.50 7.34%
Unlock

P/S ratio

Current 0.41 15.67%
2025
0.42 0.70%
Unlock
2026
0.38 7.86%
Unlock
2027
0.35 9.00%
Unlock
2028
0.31 11.26%
Unlock
2029
0.29 7.35%
Unlock

Current Theratechnologies Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RESEARCH CAPITAL CORPORATION
Locked
Locked
Locked Dec 17 2024
LEEDE JONES GABLE
Locked
Locked
Locked Oct 10 2024
RESEARCH CAPITAL CORPORATION
Locked
Locked
Locked Oct 09 2024
Analyst Rating Date
Locked
RESEARCH CAPITAL CORPORATION:
Locked
Locked
Dec 17 2024
Locked
LEEDE JONES GABLE:
Locked
Locked
Oct 10 2024
Locked
RESEARCH CAPITAL CORPORATION:
Locked
Locked
Oct 09 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today